Home > Magazine Archives > Jan. 31 - Feb. 28, 2011 Issue > Features
Resveratrol: Not a Silver Bullet?
GlaxoSmithKline has halted the development of SRT501, an experimental drug based on resveratrol, but that doesn't mean the pharmaceutical firm has stopped developing any medicines based on the compound. Wine Spectator assistant editor Stephanie Cain explains.
To continue reading this page, become a WineSpectator.com member today!
Do you have a Wine Spectator magazine subscription? Save 50% on your Online Membership right now!
Log In If You're Already a WineSpectator.com Member
